Portfolio

Round includes participation from Medtronic and top healthcare investors MIAMI, July 16, 2026 (GLOBE NEWSWIRE) — RapidPulse, Inc., a medical technology company developing next-generation aspiration technology for the treatment of acute ischemic stroke, today announced the close of a $48 million Series B financing. The raise, which drew substantial investor interest, was co-led by Medtronic, […]

Aimbient unites predictive, real-time and retrospective intelligence on one platform to improve operational efficiency, quality, safety and education NEW YORK, July 7, 2026 /PRNewswire/ — Surgical Safety Technologies (SST), the company that pioneered procedural intelligence inside the operating room, today announced it is becoming Aimbient™, the only procedural ambient AI platform built to transform how health systems

350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) — Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical

Expanded collaboration brings structured virtual care to CAR-T patients during the highest-risk period following infusion NASHVILLE, Tenn. & FORT WORTH, Texas–(BUSINESS WIRE)–Reimagine Care, the leading virtual oncology care platform, and The Center for Cancer and Blood Disorders (The Center), one of the largest community oncology practices in Texas, today announced an expansion of their collaboration to support

Endovascular Engineering Inc. (E2) has completed an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest. Additional monetary support came from Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, two existing but undisclosed strategic investors, and a new global strategic backer. The new financing will help support commercialization of E2’s

Pivotal Japan-based study evaluates efficacy and safety of non-invasive HIFU system in pancreatic cancer, complementing ongoing U.S. clinical program PALO ALTO, Calif., June 1, 2026 /PRNewswire/ — Sonire Therapeutics, a U.S.-based clinical-stage medical device company, today announced the completion of patient enrollment in SUNRISE-I, a randomized controlled trial evaluating the safety and efficacy of its proprietary High-Intensity Focused

Tegavivint was generally well tolerated and demonstrated monotherapy clinical responses with clear on-target Wnt/b-catenin pathway inhibition in patients with Wnt-pathway mutated advanced hepatocellular carcinoma (HCC) In second- and third-line patients, tegavivint achieved an overall response rate (ORR) of 22%, disease control rate of 89%, and median progression-free survival (mPFS) of 8 months Tegavivint, the first

Reimagine Care partners with health systems and oncology providers to deliver tech-enabled, at-home cancer care by combining an AI-powered virtual assistant with a 24/7 team of clinical experts. Pulse 2.0 interviewed Reimagine Care chief growth officer John Elliott to learn more. John Elliott’s Background Could you tell me more about your background? Elliott said: “I’ve spent the last

Bon Secours Mercy Health to deploy REVELOHEALTH’s iCALIBRATE™ platform across its physician network DALLAS, May 27, 2026 /PRNewswire/ — REVELOHEALTH, a leading healthcare information technology company focused on contract integrity and claims repricing, today announced a strategic investment from Accrete Health Partners, the digital venture arm of Bon Secours Mercy Health (BSMH). The investment reflects a shared focus on improving contract

SNTX-2643 is a novel, investigational, state-selective serotonin transporter modulator being developed for anxiety disorders Company also announces appointment of Cole Brown, M.D., as Chief Medical Officer and formation of a Clinical Advisory Board CAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ — Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric

Industry Veteran Dave Amerson Joins Board of Directors; OSF Ventures Joins Investment Syndicate as Company Prepares for Upcoming Presentation at ATS 2026 MENLO PARK, Calif., May 13, 2026 /PRNewswire/ — Apreo Health, a clinical-stage medical device company pioneering a tissue-sparing treatment for severe emphysema, today announced the appointment of David Amerson to its Board of Directors and a strategic investment

A personalized DNA vaccine targeting up to 40 patient-specific neoantigens generated robust immune responses and encouraging survival outcomes in patients with MGMT-unmethylated glioblastoma in a small Phase I clinical trial, according to new findings published in Nature Cancer. The study evaluated GNOS-PV01, a personalized therapeutic cancer vaccine developed by Geneos Therapeutics in collaboration with researchers at

Read the full article here.

Led by Santé, the funding will support completion of the world’s first randomized HIFU trial for pancreatic cancer, and accelerate U.S. clinical programs for the company’s anesthesia-free, outpatient sonic therapy PALO ALTO, Calif., April 15, 2026 /PRNewswire/ — Sonire Therapeutics, a U.S. based clinical-stage medical device company, today announced $18M in Series A financing. The round was led

Gilde Healthcare and Norwest co-led round to commercialize the Hēlo® Thrombectomy Platform MENLO PARK, Calif., April 7, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE), today announced an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors

HALIFAX, NS, March 31, 2026 /PRNewswire/ – ABK Biomedical and the University of Missouri Research Reactor (MURR) are powering the next generation of cancer treatment. Today, the two partners signed a long-term agreement naming MURR as the primary irradiation partner for Eye90 microspheres®, an advanced Yttrium-90 (Y-90) radioembolization therapy designed to fight liver cancer. This strategic partnership builds

Endogenex has raised $50 million in venture capital financing to complete the development of its minimally invasive procedure for Type 2 diabetes and bring its tech to the FDA. The fundraising comes shortly after the company delivered initial clinical study results showing its pulsed electric field system met its safety goals and led to metabolic

Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient has been

VS3 Medical has announced it has commenced enrolment in its international first-in-human (FIH) study evaluating the VS3 Medical stent system for patients with symptomatic venous sinus stenosis. The first enrolled cases were presented at the 2026 Society of NeuroInventional Surgery (SNIS) Cerebral Venous and Cerebrospinal Fluid (CSF) Disorders Summit (5–7 March, Colorado Springs, USA). “Patients who

WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) — Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for KST-6051, an investigational, oral, small-molecule inhibitor designed to target